Phosphorus metabolism in chronic kidney disease

Area of Science:

• Nephrology
• Endocrinology
• Mineral Metabolism

Background:

• Phosphorus homeostasis and secondary hyperparathyroidism in chronic kidney disease (CKD) are complex processes.
• Fibroblast Growth Factor 23 (FGF23) has emerged as a critical regulator linking mineral metabolism, vitamin D, and parathyroid hormone (PTH).
• FGF23 levels rise early in CKD, preceding significant changes in phosphorus or vitamin D, with developing resistance in advanced stages.

Purpose of the Study:

• To review the current understanding of phosphorus homeostasis and secondary hyperparathyroidism in CKD.
• To highlight the role of FGF23 in mineral metabolism disturbances within CKD.
• To discuss the clinical implications of FGF23 and phosphorus levels in CKD patients.

Main Methods:

• Review of recent literature on FGF23, phosphorus, vitamin D, and PTH in CKD.
• Analysis of epidemiological data relating phosphorus levels to adverse outcomes.
• Discussion of emerging evidence on FGF23 as a prognostic marker in CKD.

Main Results:

• FGF23 increases early in CKD and is linked to parathyroid resistance.
• Elevated serum phosphorus is associated with adverse outcomes across various populations, including CKD.
• Increased FGF23 levels correlate with mortality, left ventricular hypertrophy, and CKD progression, independent of phosphorus levels.

Conclusions:

• FGF23 is a crucial factor in CKD mineral metabolism and secondary hyperparathyroidism.
• The role of FGF23 in CKD progression and outcomes warrants further investigation.
• Optimal phosphorus targets and the clinical utility of FGF23 in CKD management are areas of ongoing research.